Showing 1765 results
-
Press release /Novartis Pharmaceuticals Corporation (NPC) has agreed to certain provisions relating to specialty pharmacies as part of an addendum to its existing corporate integrity agreement (CIA), which will…
-
Press release /Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as…
-
Press release /Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months.CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the…
-
Press release /Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk…
-
Press release /Treatment with Cosentyx® (secukinumab) resulted in a 72% reduced flare risk versus placebo, with improvement in disease activity over two years across both enthesitis-related arthritis (ERA) and…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr Der Nettoumsatz stieg um +4% (kWk1, –2% USD), wobei sich das operative Kernergebnis um +8% (kWk, 0% USD) verbesserte Innovative…
-
Press release /The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in…
-
Press release /European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with…
-
Press release /If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix…
-
Ad hoc release /Net sales grew 6% (cc[1], +3% USD) mainly driven by: Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indications Entresto more than doubled to USD 271 million (+113…